|
FDA approves first gene therapy to treat adults with Hemophilia B
|
22 November 2022 |
|
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
|
31 August 2022 |
|
FDA approves first systemic treatment for alopecia areata
|
13 June 2022 |
|
FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
|
19 May 2022 |
|
FDA limits use of Janssen COVID-19 vaccine to certain individuals
|
06 May 2022 |
|
FDA approves first generic of Symbicort to treat asthma and COPD
|
15 March 2022 |
|
FDA approves treatment for wider range of patients with heart failure
|
24 February 2022 |
|
FDA takes key action by approving second COVID-19 vaccine
|
31 January 2022 |
|
FDA authorizes additional oral antiviral for treatment of COVID-19 in certain adults
|
27 December 2021 |
|
FDA authorizes first oral antiviral for treatment of COVID-19
|
22 December 2021 |
|
FDA expands eligibility for Pfizer-BioNTech COVID-19 booster dose to 16- and 17-year-olds
|
09 December 2021 |
|
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age
|
29 October 2021 |
|
FDA, NIH, and 15 private organizations join forces to increase effective gene therapies for rare diseases
|
28 October 2021 |
|
FDA takes additional actions on the use of a booster dose for COVID-19 vaccines
|
21 October 2021 |
|
FDA awards 11 grants to clinical trials to develop new medical products for rare disease treatments
|
14 October 2021 |
|
FDA approves innovative treatment for pediatric patients with congenital athymia
|
08 October 2021 |
|
FDA authorizes software that can help identify prostate cancer
|
21 September 2021 |
|
FDA advances data, IT modernization efforts with new office of digital transformation
|
15 September 2021 |
|
FDA approves first COVID-19 vaccine
|
24 August 2021 |
|
FDA approves new treatment for Pompe disease
|
06 August 2021 |